The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Engineering of glycosylation in yeast and other fungi: current state and perspectives
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835 · cited 1×
“These are the type of glycans found on the Fc part of human IgG, where this particular non-fucosylated structure has great advantages over the naturally occurring core-fucosylated counterpart: it increases the potential of the antibody for antibody-dependent cytotoxicity, which is desirable in many anti-tumor and anti…”
BackgroundShinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413 · cited 1×
“These are the type of glycans found on the Fc part of human IgG, where this particular non-fucosylated structure has great advantages over the naturally occurring core-fucosylated counterpart: it increases the potential of the antibody for antibody-dependent cytotoxicity, which is desirable in many anti-tumor and anti…”
BackgroundUmaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764 · cited 1×
“These are the type of glycans found on the Fc part of human IgG, where this particular non-fucosylated structure has great advantages over the naturally occurring core-fucosylated counterpart: it increases the potential of the antibody for antibody-dependent cytotoxicity, which is desirable in many anti-tumor and anti…”
BackgroundHumanization of yeast to produce complex terminally sialylated glycoproteins
Hamilton, S. R., Davidson, R. C., Sethuraman, N., Nett, J. H., Jiang, Y., Rios, S., Bobrowicz, P., Stadheim, T. A., Li, H., Choi, B.-K., et al. (2006) · Science · doi:10.1126/science.1130256 · Cited by 511
Overview of N- and O-linked oligosaccharide structures found in various yeast species
Gemmill, T. R., & Trimble, R. B. (1999) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(98)00126-3 · Cited by 439
Asparagine-linked glycosylation in the yeast Golgi
Dean, N. (1999) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(98)00132-9 · Cited by 188 · cited 1×
“cerevisiae, in which the Nglycosylation pathway was originally characterized (Dean 1999; Kukuruzinska et al. 1987) (Figs.”
Background
Cited by
(2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00075 · Cited by 1,611
Ahmad, M., Hirz, M., Pichler, H., & Schwab, H. (2014) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-014-5732-5 · Cited by 989
Recombinant Protein Production in Yeasts
Mattanovich, D., Branduardi, P., Dato, L., Gasser, B., Sauer, M., & Porro, D. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-433-9_17 · Cited by 357
Production of recombinant proteins by yeast cells
Çelik, E., & Çalık, P. (2012) · Biotechnology Advances · doi:10.1016/j.biotechadv.2011.09.011 · Cited by 337
Ghaderi, D., Zhang, M., Hurtado-Ziola, N., & Varki, A. (2012) · Biotechnology and Genetic Engineering Reviews · doi:10.5661/bger-28-147 · Cited by 320
“…USA Pig +++ Cytokines Aranesp® Darbepoetin a Amgen CHO ++ Avonex® Interferon b-1a Biogen Idec, Inc. CHO ++ NeoRecormon Epoetin b Hoffmann-La Roche Ltd. CHO ++ Procrit®, Epogen® Epoetin a Amgen, Centocor Ortho Biotech Inc. CHO ++ Rebif® Interferon b-1a Pfizer, Inc., EMD Serono, Inc. CHO ++”
BackgroundInfluential
Metadata
- Authors
- De Pourcq, K., De Schutter, K., & Callewaert, N.
- Venue
- Applied Microbiology and Biotechnology
- Published
- 2010-06-29
- Volume
- 87
- Issue
- 5
- Pages
- 1617-1631
- ISSN
- 0175-7598 (ISSN-L)
- 1432-0614
- OpenAlex
- W2052654155
- Cited by
- 160
- References
- 6
- FWCI
- 4.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.